Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
AssigneesDana-Farber Cancer Institute, Inc., Genus Oncology, LLC
InventorsDonald W. Kufe, Surender Kharbanda
Life of this patent
Estimating the term…
Abstract
The treatment of human epidermal growth factor receptor 2-positive (HER2+) cancers using a combination of anti-mucin 1 (anti-MUC1) therapy and anti-human epidermal growth factor receptor 2 (anti-HER2) therapy is described, such as the treatment of trastuzamab-resistant cancers, both primary and acquired, using the same combination of agents.
Claims41
A method of treating a human subject having mucin 1, cell surface associated (MUC1)-positive/human epidermal growth factor receptor 2-positive (HER2)-positive cancer comprising administering to said subject:
- (a) a MUC1 peptide of at least 4 consecutive MUC1 residues and no more than 20 consecutive MUC1 residues and comprising the sequence CQC (SEQ ID NO:4), wherein the amino-terminal cysteine of CQC is covered on its NH2-terminus by at least one amino acid residue that need not correspond to the native MUC-1 transmembrane sequence;
- and
- (b) an anti-HER2 therapy,
- wherein the cancer overexpresses HER2 as compared to a similar non-cancerous cell.
A method of treating a human subject having mucin 1, cell surface associated (MUC1)-positive/human epidermal growth factor receptor 2 (HER2)-positive cancer comprising administering to said subject:
- (a) a MUC1 peptide of at least 4 consecutive MUC1 residues and no more than 20 consecutive MUC1 residues and comprising the sequence CQC (SEQ ID NO:4), wherein the amino-terminal cysteine of CQC is covered on its NH2-terminus by at least one amino acid residue that need not correspond to the native MUC-1 transmembrane sequence;
- and
- (b) an anti-HER2 therapy,
- wherein the subject has previous received an anti-HER2 therapy.
A method of treating a human subject having mucin 1, cell surface associated (MUC1)-positive/human epidermal growth factor receptor 2 (HER2)-positive cancer comprising:
- (a) assessing the expression of HER2 in a tumor cell of said subject;
- (b) administering a MUC1 peptide of at least 4 consecutive MUC1 residues and no more than 20 consecutive MUC1 residues and comprising the sequence CQC (SEQ ID NO:4), wherein the amino-terminal cysteine of CQC is covered on its NH2-terminus by at least one amino acid residue that need not correspond to the native MUC-1 transmembrane sequence;
- and
- (c) administering an anti-HER2 therapy.
Dependencies are inferred from the claim text.